MetaVia Regains Nasdaq Compliance, Advances Cardiometabolic Drug Candidates

MetaVia's Compliance Regained: A Step Forward in Cardiometabolic Innovation

MetaVia Inc., a clinical-stage biotechnology company specializing in the treatment of cardiometabolic diseases, announces a significant milestone by regaining compliance with Nasdaq's minimum bid price requirement as of December 19, 2025. This accomplishment, in accordance with Nasdaq Listing Rule 5550(a)(2), signals the closure of a listing matter and reassures stakeholders that MetaVia meets all necessary criteria for continued presence on the Nasdaq Capital Market. This compliance is a crucial step for the company as it continues to advance its innovative drug candidates focused on addressing widespread health issues linked to obesity and metabolic dysfunction.

At the forefront of MetaVia's endeavors are two promising drug candidates: DA-1726 and vanoglipel. DA-1726, an oxyntomodulin (OXM) analogue, is designed specifically for obesity treatment. It acts as a dual agonist for glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), effectively decreasing food intake while increasing energy expenditure. Early results from a Phase 1 trial show promise for DA-1726 in achieving superior weight loss and improved glucose control. This candidate represents MetaVia's innovative approach in the fight against obesity, a condition that affects millions and is linked to various chronic diseases.

In addition to DA-1726, MetaVia is also advancing vanoglipel, a G-protein-coupled receptor 119 (GPR119) agonist aimed at treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). Pre-clinical studies have indicated that vanoglipel may reduce liver inflammation and enhance metabolic function, while also promoting weight loss and better glucose regulation. A recent Phase 2a clinical study demonstrates its direct hepatic action, suggesting significant therapeutic potential. Both candidates reflect MetaVia’s commitment to innovation in the biotechnology sector, targeting critical health challenges associated with cardiometabolic diseases.

Beyond the compliance announcement and the advancement of its drug candidates, MetaVia's progress underscores its strategic positioning within the biotechnology industry. The company’s focus on developing treatments for conditions that have a profound impact on global health, such as obesity and MASH, highlights its role in addressing urgent medical needs. As MetaVia continues to develop and test its therapies, it not only aims to enhance patient outcomes but also solidifies its standing as a key player in the ongoing transformation of cardiometabolic disease management.

For further details on their initiatives and advancements, visit www.metaviatx.com.